Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer.

Pharmacogenomics - 1 Feb 2014

Khrunin Andrey V, Khokhrin Denis V, Moisseev Alexey A, Gorbunova Vera A, Limborska Svetlana A

Abstract excerpt

AIM: Cisplatin and its analogs are potent antitumor agents. However, their use is restricted by significant variability in tumor response and toxicity. There is a great need to identify genetic markers to predict the most important adverse events and patient outcomes. MATERIALS & METHODS: We have evaluated the association between polymorphisms in 106 genes involved mainly in xenobiotic metabolism, DNA repair, the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Pharmacological
Share to Cisplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Drug-Related Side Effects and Adverse Reactions

Share to Genetic Association Studies

Share to Inactivation, Metabolic

Share to Ovarian Neoplasms

Share to Pharmacogenetics

Source

Identifiers

PMID: 24533712
DOI: 10.2217/pgs.13.237

Genes

EPHX1
ERCC5
LIG3
MUTYH
NAT2
NQO1
RAD52
TPMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer.PMID 24533712Read ↗

Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer.Semantic proximity Read ↗

Pharmacogenomics of Cisplatin-Based Chemotherapy in Ovarian Cancer Patients of Different Ethnic OriginsSemantic proximity Read ↗

Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer.Semantic proximity Read ↗

Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patientsSemantic proximity Read ↗

[Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients from Yakutia].Semantic proximity Read ↗

Genetic markers for prediction of treatment outcomes in ovarian cancer.Semantic proximity Read ↗

Pharmacogenomics of taxane/platinum therapy in ovarian cancer.Semantic proximity Read ↗

Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer.Semantic proximity Read ↗

Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?Semantic proximity Read ↗

Pharmacogenetic Analyses of a Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma With Fluorouracil and Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische OnkologieSemantic proximity Read ↗

Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms.Semantic proximity Read ↗

Genetic variability of DNA repair mechanisms and glutathione-S-transferase genes influences treatment outcome in osteosarcoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.